Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Cardiology"
DOI: 10.1001/jamacardio.2022.3750
Abstract: Key Points Question When are the clinical benefits of the sodium glucose cotransporter 2 inhibitor dapagliflozin first apparent among patients with heart failure with mildly reduced or preserved ejection fraction? Findings In this prespecified secondary… read more here.
Keywords: heart failure; mildly reduced; patients heart; heart ... See more keywords